Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank De Wolf

Showing results (81-90 of 105) with videos related to

Pageof 11
Sort By:
Plos Medicine|April 6, 2012
No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trialMarlous L Grijsen, Radjin Steingrover, Ferdinand W N M Wit, et al.
Plos One|February 21, 2012
Single nucleotide polymorphism in gene encoding transcription factor Prep1 is associated with HIV-1-associated dementiaSebastiaan M Bol, Thijs Booiman, Daniëlle van Manen, et al.
AIDS (London, England)|April 20, 2002
Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohortJeanne P Dieleman, Marielle Jambroes, Inge C Gyssens, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 1, 2019
Perspective: Clinical relevance of the dichotomous classification of Alzheimer's disease biomarkers: Should there be a "gray zone"?Kevin McRae-McKee, Chinedu T Udeh-Momoh, Geraint Price, et al.
Artificial Intelligence in Medicine|June 16, 2009
A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapyDechao Wang, Brendan Larder, Andrew Revell, et al.
Antiviral Therapy|May 17, 2007
The development of artificial neural networks to predict virological response to combination HIV therapyBrendan Larder, Dechao Wang, Andrew Revell, et al.
International Journal of Epidemiology|October 13, 2009
Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries, Marcel Zwahlen, Ross Harris, et al.
AIDS (London, England)|August 24, 2011
Rising HIV-1 viral load set point at a population level coincides with a fading impact of host genetic factors on HIV-1 controlDaniëlle van Manen, Luuk Gras, Brigitte D Boeser-Nunnink, et al.
AIDS (London, England)|September 22, 2006
Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral useGrace P S Kwong, Azra C Ghani, Richard A Rode, et al.
Lancet (London, England)|August 8, 2006
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysisMargaret T May, Jonathan A C Sterne, Dominique Costagliola, et al.
Pageof 11

Showing results (81-90 of 105) with videos related to

Sort By:
Pageof 11
Plos Medicine|April 6, 2012
No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trialMarlous L Grijsen, Radjin Steingrover, Ferdinand W N M Wit, et al.
Plos One|February 21, 2012
Single nucleotide polymorphism in gene encoding transcription factor Prep1 is associated with HIV-1-associated dementiaSebastiaan M Bol, Thijs Booiman, Daniëlle van Manen, et al.
AIDS (London, England)|April 20, 2002
Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohortJeanne P Dieleman, Marielle Jambroes, Inge C Gyssens, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|October 1, 2019
Perspective: Clinical relevance of the dichotomous classification of Alzheimer's disease biomarkers: Should there be a "gray zone"?Kevin McRae-McKee, Chinedu T Udeh-Momoh, Geraint Price, et al.
Artificial Intelligence in Medicine|June 16, 2009
A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapyDechao Wang, Brendan Larder, Andrew Revell, et al.
Antiviral Therapy|May 17, 2007
The development of artificial neural networks to predict virological response to combination HIV therapyBrendan Larder, Dechao Wang, Andrew Revell, et al.
International Journal of Epidemiology|October 13, 2009
Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries, Marcel Zwahlen, Ross Harris, et al.
AIDS (London, England)|August 24, 2011
Rising HIV-1 viral load set point at a population level coincides with a fading impact of host genetic factors on HIV-1 controlDaniëlle van Manen, Luuk Gras, Brigitte D Boeser-Nunnink, et al.
AIDS (London, England)|September 22, 2006
Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral useGrace P S Kwong, Azra C Ghani, Richard A Rode, et al.
Lancet (London, England)|August 8, 2006
HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysisMargaret T May, Jonathan A C Sterne, Dominique Costagliola, et al.
Pageof 11